Call for Abstract

19th International Conference on Medicinal Chemistry &
Multi Targeted Drug Delivery, will be organized around the theme “Scientific Novelty and Advanced Perception in Medicinal Chemistry”

MedChem & MTDD 2018 is comprised of keynote and speakers sessions on latest cutting edge research designed to offer comprehensive global discussions that address current issues in MedChem & MTDD 2018

Submit your abstract to any of the mentioned tracks.

Register now for the conference by choosing an appropriate package suitable to you.

  • Track 1-1 Target discovery and validation
  • Track 1-2Molecular modelling
  • Track 1-3Drug receptor interactions
  • Track 1-4Pro drug synthesis and drug targeting
  • Track 1-5Toxicity, and therapeutic applications of antibiotics, antifungals, and antivirals
  • Track 2-1Drug-Receptor Interactions
  • Track 2-2Development of screening and assay methods
  • Track 2-3Protein biochemistry.
  • Track 2-4Organic synthesis of ligands and inhibitors
  • Track 2-5Considerations for the Use of Computational Chemistry Techniques by Medicinal Chemists
  • Track 2-6Physicochemical Properties and Drug Design
  • Track 2-7Drug Metabolism
  • Track 2-8 Pharmacokinetics
  • Track 2-9The Biological Evaluation of New Compounds
  • Track 2-10Molecular biology and genetic engineering
  • Track 3-1Research Strategies
  • Track 3-2Methodologies and literature concerning the mechanisms of drug action and drug metabolism
  • Track 4-1Biochemical mechanisms for the biotransformation of drugs and foreign compounds
  • Track 4-2Reaction mechanisms
  • Track 4-3Ultrastructural considerations,induction mechanisms, methodology, kinetics of inhibition
  • Track 4-4Activation, steroid and amine metabolism.
  • Track 4-5NS3, the protease of flaviviruses such as dengue and West Nile virus
  • Track 4-6Combined phenotypic/target-oriented screening approaches, and their application on anti-infective drug discovery
  • Track 4-7Targeting of host factors involved in virus replication
  • Track 4-8Targeting of host factors involved in virus replication
  • Track 5-1BACE Inhibitors
  • Track 5-2Passive Immunotherapy
  • Track 5-3Enhancing Cognition
  • Track 5-4Anti-Amyloid Treatment
  • Track 5-5Targets for future drugs
  • Track 6-1DNA Structure
  • Track 6-2Gene Cloning - Propagation of Genetic Material in Alternative Host Systems
  • Track 6-3Expression of Cloned Genes
  • Track 6-4Uses of Cloned Human Proteins
  • Track 7-1Personalized Medicine
  • Track 7-2Naturopathy and Acupuncture as a secondary medical system
  • Track 7-3Drug resistance by misuse of medications
  • Track 7-4Modernising Traditions
  • Track 7-5Protection and piracy
  • Track 8-1Plant-pathogen interactions
  • Track 8-2DNA microarrays
  • Track 8-3Advances in plant Tissue culture and revolutionizing agriculture
  • Track 8-4Plant biotech for agriculture Improvement
  • Track 9-1Can only drug cure a disease?
  • Track 9-2Antioxidants
  • Track 9-3Why are pharmaceuticals around?
  • Track 9-4Nutraceutical Supplements as convenient and effective
  • Track 9-5Bridging the gap between food and medicine
  • Track 10-1Peptides with dual Antimicrobial and anticancer activities
  • Track 10-2Anticancer activitiy of maize Bioactive peptides
  • Track 10-3Contemporary materials safety
  • Track 10-4A brief description on how EDTA is measured in blood
  • Track 11-1Ligand and structure based drug design
  • Track 11-2Computational Chemistry
  • Track 11-3Molecular modelling
  • Track 11-4Enzyme as target
  • Track 11-5Receptor as target
  • Track 11-6QSAR/QSPR Quantitative structure activity/property relationships
  • Track 12-1ADME (adsorption,distribution,metabolism and excretion) of drugs
  • Track 12-2Metabolism and toxicology
  • Track 12-3Antiviral and antimicrobial activity
  • Track 12-4Drug receptor interaction
  • Track 12-5Kojic acid as a tyrosine inhibitor
  • Track 13-1 GC-MS
  • Track 13-2LC-ITIR
  • Track 13-3LC-NMR
  • Track 13-4Chemical fingerprinting and quality control
  • Track 14-1Magnetoelectric nanoparticles
  • Track 14-2Nanoparticle drug delivery
  • Track 14-3Problems of multidrug resistance in cancer therapies
  • Track 14-4Taxoids as potent cytotoxic agents for tumour targeting drug delivery
  • Track 15-1Dementias responsible for greatest burden of neurodegenerative diseases
  • Track 15-2Causes and treatments
  • Track 15-3Motor neurone diseases
  • Track 15-4Huntington’s disease.
  • Track 16-1A pattern of depressed resistancein autism
  • Track 16-2Do vaccines for children cause autism?
  • Track 16-3Research supports vaccinating
  • Track 16-4Autism genetic risk factors
  • Track 16-5Autism environmental risk factors
  • Track 17-1Determinants of Infectious diseases
  • Track 17-2Emergence and Reemergence of infectious diseases
  • Track 17-3HIV/AIDS:Newly emerging infectious diseases
  • Track 17-4Research on emerging Infectious diseases
  • Track 17-5Preventing emerging infectious diseases:A strategy for the 21st century
  • Track 17-6Zika virus
  • Track 18-1How do antibiotics work?
  • Track 18-2What are the side effects?
  • Track 18-3Main types of antibiotics
  • Track 18-4Biological antibiotics derived from molds
  • Track 18-5Synthetic antibiotics derived from dyes
  • Track 19-1Personalized medicines: A decade of advancements
  • Track 19-2Cancer genomics
  • Track 19-3Pharmacogenomics
  • Track 19-4Good for patients but bad for drug companies
  • Track 19-5Ramifications of illicit drug markets in society
  • Track 20-1Chemotherapeutic agents
  • Track 20-2Microorganisms that produce antibiotics
  • Track 20-3Antimicrobial peptides: Promising compounds against pathogenic microorganisms
  • Track 20-4Discovery of penicillin
  • Track 20-5Discovery of sulphonamides
  • Track 22-1Binding kinetics and pathways of ligands to GPCRs
  • Track 22-2• Aurora A kinase ,a priority pharmaceutical target for treatment of cancer
  • Track 22-3Novel adjuvants designed for improving vaccine efficacy
  • Track 23-1Role of computational biology
  • Track 23-2Pioneering digital health and smart drug delivery systems
  • Track 23-3Ligand binding studies
  • Track 23-4Phage display technology for clinical application of protein drugs
  • Track 24-1Potential use of stem cells for regeneration
  • Track 24-2Harnessing yeast organelles for metabolic engineering
  • Track 24-3Si-RNA a tool in chemical biology
  • Track 24-4Discovery of biomolecules through metagenomics
  • Track 24-5Protomics
  • Track 25-1High throughput screening
  • Track 25-2Target identification
  • Track 25-3Target validation
  • Track 25-4Screening cascade-Lead optimization
  • Track 26-1Application of integrated data from the physical and biological sciences to problems of chemotherapy
  • Track 26-2Transport of drugs to site of action
  • Track 26-3Biotransformation of drugs
  • Track 26-4Interaction of drugs with enzyme systems
  • Track 26-5Recent advances in drug design
  • Track 27-1New Drugs to Eliminate Malaria
  • Track 27-2New Strategy for the Discovery of Drugs
  • Track 27-3New Drug Discovery Technique to Target a Class of Enzymes
  • Track 27-4 Serelaxin - Breakthrough Therapy in the Treatment of Heart Failure
  • Track 27-5Discovery of Ebola Protein could Lead to Drug Development
  • Track 27-6New Drug could Treat Most Aggressive Form of Lung Cancer
  • Track 27-7Medicinal chemistry of drugs used in diabetic cardiomyopathy.
  • Track 28-1 Advantages of fluorine in drug development
  • Track 28-2Fluorinated drugs in the treatment of cardiovascular diseases
  • Track 28-3Fluorinated drugs in the treatment of cardiovascular diseases
  • Track 28-4Fluorinated antibacterial agents
  • Track 28-5Fluorinated azole antifungal agents
  • Track 28-6Fluorinated anti-inflammatory agents
  • Track 28-7Fluorinated anticancer agents
  • Track 29-1Mechanisms of action
  • Track 29-2spectrum of coverage, resistance patterns
  • Track 29-3chemical and biologic properties of agents used to prevent or treat infectious diseases
  • Track 30-1Therapeutic antibodies, and drug targets
  • Track 30-2Protein-protein-interactions and Protein-lipid interactions
  • Track 30-3Thermodynamics and kinetics of protein-ligand interactions
  • Track 31-1Integrates aspects of medicinal chemistry and pharmacokinetics with the physiology,
  • Track 31-2Include ion channels and enzymes relevant to cardiovascular disease
  • Track 32-1Biological Mass Spectrometry
  • Track 32-2Modern ionization methods and mass analyzers
  • Track 32-3Small molecule structure assignment
  • Track 32-4• Quantitative assay development by LC-MS and metabolomics quantitative discovery-
  • Track 34-1Design and synthesis of target compounds: thiazoles, thiophenes, benzimidazoles and boronic acid derivatives as anticancer and anti-diabetic agents.
  • Track 34-2Synthesis of neuroprotective and multi target directed ligand molecules and their pharmacokinetic/pharmacodynamic (PK/PD) studies.
  • Track 34-3Ionic liquid mediated C-C and C=C bond forming reactions.
  • Track 34-4Re purposing of existing drug molecules for improved PK/PD profiling by modification of non pharmacophoric parts.
  • Track 35-1Monoclonal antibodies
  • Track 35-2Oncolytic virus therapy
  • Track 35-3Cancer vaccines
  • Track 36-1Lead selection from HTS and virtual screening
  • Track 36-2General design principles
  • Track 36-3 Drug design with defined target structure
  • Track 37-1High resolution-mass spectrometry (HR-MS) technology
  • Track 37-2Data-mining tools
  • Track 37-3AB SCIEX TripleTOF™ 5600 System for the study of drug metabolism in BDC rats and CYP inhibition cocktail assays.
  • Track 38-1Histone deacetylases (HDACs) and histone acetylases (HATs
  • Track 38-2Leukaemia-associated fusion proteins
  • Track 38-3Leukaemia-associated fusion proteins
  • Track 39-1 Nanoparticles that deliver three anti-cancer drugs to the lymph nodes
  • Track 39-2 Sustained drug delivery using a hydrogen
  • Track 39-3 Photosensitizing agent to enhance the ability of drug carrying nanoparticles
  • Track 39-4Nanotechnology in Drug Delivery - Heart Disease
  • Track 39-5 Carbon nanofibers penetrate diseased cells
  • Track 39-6Nanotechnology in Drug Delivery - Aging and other areas
  • Track 40-1Pharmacokinetics
  • Track 40-2Toxicology
  • Track 40-3Posology
  • Track 41-1Anaesthetic vaporizer
  • Track 41-2Tinctures‎
  • Track 41-3Transdermal patches‎
  • Track 42-1Survey of major drug classes with emphasis on molecular mechanisms of action
  • Track 42-2Survey of methods used in contemporary pharmaceutical research including computational and combinatorial approaches
  • Track 43-1Platinum based anticancer drugs
  • Track 43-2Objectives of TDDS
  • Track 43-3Bioligand and its attachement to protein target